CompletedPhase 2/3

Methylphenidate in Myotonic Dystrophy Type 1

Canada28 participantsStarted 2008-06

Plain-language summary

The purpose of this study is to determine whether methylphenidate is effective in the treatment of excessive daytime sleepiness due to myotonic dystrophy type 1 (DM1).

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * adults * Epworth score ≥ 10 * Diagnosis of myotonic dystrophy type 1 Exclusion Criteria: * hypersensibility to methylphenidate * Pregnancy * Patients who receive drugs that interfere with methylphenidate * Cognitive impairment * Sleep apnea

What they're measuring

Change from baseline of excessive daytime sleepiness

Timeframe: 3 weeks after treatment

Trial details

NCT IDNCT01421992

SponsorLaval University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-08

View on ClinicalTrials.gov More Dystrophia Myotonica 1 trials